Anat O. Stemmer-Rachamimov, MD, University of Milan
Affiliations: | Pathology | Masssachusetts General Hospital, Boston, MA, United States |
Area:
Heredetary Brain Tumor Syndrome, NeuropathologyOphthalmic Pathology, SurgicalsWebsite:
http://www.massgeneral.org/doctors/doctor.aspx?id=17876Google:
"Anat Stemmer-Rachamimov"Bio:
http://www.dfhcc.harvard.edu/membership/profile/member/1151/0/
Mean distance: 16.47 (cluster 24) | S | N | B | C | P |
Cross-listing: Neuropathology Tree
Parents
Sign in to add mentorE. Tessa Hedley-Whyte | post-doc | 1999-2000 | Harvard Medical School and Masssachusetts General Hospital |
David N. Louis | post-doc | 1999-2001 | Harvard Medical School and Masssachusetts General Hospital |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Batool SM, Escobedo AK, Hsia T, et al. (2024) Clinical utility of a blood based assay for the detection of IDH1.R132H-mutant gliomas. Nature Communications. 15: 7074 |
Staedtke V, Topilko P, Le LQ, et al. (2023) Existing and Developing Preclinical Models for Neurofibromatosis Type 1-Related Cutaneous Neurofibromas. The Journal of Investigative Dermatology |
Prabhakar S, Beauchamp RL, Cheah PS, et al. (2022) Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2. Molecular Therapy. Methods & Clinical Development. 26: 169-180 |
Freeman SS, Sade-Feldman M, Kim J, et al. (2022) Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma. Cell Reports. Medicine. 3: 100500 |
Chang LS, Oblinger JL, Smith AE, et al. (2021) Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. Plos One. 16: e0252048 |
Li M, Li G, Kiyokawa J, et al. (2020) Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma. Acta Neuropathologica Communications. 8: 221 |
Richardson LG, Nieman LT, Stemmer-Rachamimov AO, et al. (2020) IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice. Oncoimmunology. 9: 1806662 |
Ortonne N, Carroll SL, Rodriguez FJ, et al. (2020) Assessing interobserver variability and accuracy in the histological diagnosis and classification of cutaneous neurofibromass. Neuro-Oncology Advances. 2: i117-i123 |
Freeman SS, Sade-Feldman M, Kim J, et al. (2020) Abstract 6670: Combined signals from tumor and immune cells predict outcomes of checkpoint inhibition in melanoma Immunology. 80: 6670-6670 |
Prabhakar S, Cheah PS, Zhang X, et al. (2019) Long-Term Therapeutic Efficacy of Intravenous AAV-Mediated Hamartin Replacement in Mouse Model of Tuberous Sclerosis Type 1. Molecular Therapy. Methods & Clinical Development. 15: 18-26 |